Back to Search

CHRS

Coherus Oncology, Inc. Common Stock
Data: 2026-02-02
$2.167
Price
0.32%
Change
$2.6158
52W High
$0.71
52W Low
Buy/Sell Forecast Trendline Why Moving Charts Options

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.

Quick Stats
Feb 02, 2026

56.4

AI Score

HOLD

0.14

Volume Ratio

Mar 09, 2026

Next Earnings

18

+ve Days (30d)

11

-ve Days (30d)

CHRS Stock Summary

Last updated

CHRS is currently trading at $2.167, positioned above its 200-day moving average of $1.23, indicating a long-term uptrend. The stock has a 52-week range of $0.71 to $2.6158.

Technical Analysis: The 50-day moving average stands at $1.51, which is below the current price, signaling bullish near-term momentum. The RSI (Relative Strength Index) reads , suggesting the stock is neutral with balanced momentum.

Money Flow Indicators: The Chaikin Money Flow (20-day) is , which is negative, suggesting distribution or selling pressure. Our AI-powered investment score rates CHRS at 56.4/100 with a HOLD recommendation.

CHRS Technical Chart
  • Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
  • SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
  • Options OI: Shows max open interest strikes. High OI = significant price levels.
  • Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
  • Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
  • Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
  • Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
  • Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators

Select indicators above to analyze technical patterns

Indicators will appear below the price chart with perfectly aligned dates

Volume Profile Analysis

Horizontal histogram showing volume distribution at each price level with buying/selling pressure

CHRS Price vs Max Options Open Interest
CHRS Max Change In Options Open Interest

CHRS Options - Sort by Max open Interest (near term)

2nd February 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI		 Volume Ask PC Delta Vega Volatility % change Track

CHRS Daily Out of Money Options - Sort by Max open Interest (near term)

2nd February 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI		 Volume Ask PC Delta Vega Volatility % change Track

CHRS Daily In the Money Options - Sort by Max open Interest (near term)

2nd February 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI		 Volume Ask PC Delta Vega Volatility % change Track

CHRS Most Active Options by Volume(near term)

2nd February 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike Volume OI Change in
OI		 Ask PC Delta Vega Volatility % change Track

Coherus Oncology, Inc. Common Stock is above both 50 Day and 200 Day SMA which is considered Bullish.

CHRS Moving Averages Analysis

Coherus Oncology, Inc. Common Stock has been above 50 day sma 1 times in last 30 days. Last time it was above 50 day sma was on Feb 02, 2026

Coherus Oncology, Inc. Common Stock has been above 200 day sma 1 times in last 30 days. Last time it was above 200 day sma was on Feb 02, 2026

CHRS (Coherus Oncology, Inc. Common Stock) Simple Moving Averages

Moving Averages are last updated Feb 02, 2026

Days MA
10 2.05
20 1.81
30 1.66
50 1.51
100 1.53
200 1.23

CHRS Fundamental Analysis

P/E (Forward) 41.1523
P/E (Trailing) 4.1
Market Cap ($) 272.6 million
Earnings/Share ($) 0.55
Net Proft Margin (%) 0.558
Dividend/Share ($) --
EPS Estimate Current Year ($) -1.33
EPS Estimate Next Year ($) -0.49
WallStreet Target Price ($) 6.75
Most Recent Quarter